Disease · HP_0012199
Cluster headache
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Cluster headache. Diseases, record HP_0012199. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012199
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Cluster headache
- Open Targets ID
- HP_0012199
- Highest stage of its drugs
- Phase 3, for 4 of its 12 drugs, from ClinicalTrials.gov and TTD
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EPTINEZUMAB | CHEMBL3833320 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GALCANEZUMAB | CHEMBL3707328 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SUMATRIPTAN SUCCINATE | CHEMBL1201150 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| ZOLMITRIPTAN | CHEMBL1185 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIPHENHYDRAMINE | CHEMBL657 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ERENUMAB | CHEMBL3833329 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LYSERGIDE | CHEMBL263881 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| PASIREOTIDE | CHEMBL3349607 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROCHLORPERAZINE | CHEMBL728 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CALCA | Calcitonin gene-related peptide | 2 | Calcitonin gene-related peptide inhibitor | Phase 3 | https://conductscience.org/library/genes/796 | Drugs and targets |
| CALCB | Calcitonin gene-related peptide | 2 | Calcitonin gene-related peptide inhibitor | Phase 3 | https://conductscience.org/library/genes/797 | Drugs and targets |
| CALCRL | Calcitonin gene-related peptide type 1 receptor | 2 | Calcitonin gene-related peptide type 1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/10203 | Drugs and targets |
| HTR1B | 5-hydroxytryptamine receptor 1B | 2 | Serotonin 1b (5-HT1b) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3351 | Drugs and targets |
| HTR1D | 5-hydroxytryptamine receptor 1D | 2 | Serotonin 1d (5-HT1d) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3352 | Drugs and targets |
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 1 | Succinate semialdehyde dehydrogenase inhibitor | Unknown | https://conductscience.org/library/genes/7915 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 1 | Dopamine D2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3269 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| SSTR1 | Somatostatin receptor type 1 | 1 | Somatostatin receptor 1 agonist | Phase 2 | https://conductscience.org/library/genes/6751 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04688775 | Eptinezumab in Participants With Episodic Cluster Headache | Phase 3 | 231 | 2024-08-09 | Cluster Headache, Episodic | EPTINEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02797951 | A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache | Phase 3 | 165 | 2022-02-10 | Episodic Cluster Headache, Chronic Cluster Headache | GALCANEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05064397 | A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) | Phase 3 | 131 | 2024-08-06 | Chronic Cluster Headache | EPTINEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02397473 | A Study Of Galcanezumab In Participants With Episodic Cluster Headache | Phase 3 | 109 | 2019-03-13 | Episodic Cluster Headache | GALCANEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00356603 | Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan | Phase 3 | 75 | 2017-11-20 | Migraine Disorders | SUMATRIPTAN SUCCINATE | Its record names the disease | ClinicalTrials.gov |
| NCT04066023 | Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches | Phase 2/3 | 42 | 2022-05-02 | Cluster Headache | ZOLMITRIPTAN | Its record names the disease | ClinicalTrials.gov |
| NCT02619617 | Safety and Efficacy Study of SOM230 s.c. in Cluster Headache | Phase 2 | 28 | 2020-01-13 | Cluster Headache - Episodic and Chronic | PASIREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00203242 | An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches. | Not applicable | 15 | 2011-07-06 | Cluster Headache | DIVALPROEX SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT04970355 | Efficacy of Erenumab in Chronic Cluster Headache | Phase 2 | 101 | Cluster Headache, Trigeminal Autonomic Cephalalgias, Headache Disorders, Primary, Brain Disease | ERENUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04109885 | Paracervical Injection for Headache in the Emergency Department | Phase 2 | 19 | Headache Disorders, Primary, Pain Management, Emergency Department | DIPHENHYDRAMINE, PROCHLORPERAZINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Eptinezumab vs Placebo: Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks Over Weeks 1-2 | 44 of 113 | 37 of 118 | 231 | NCT04688775 | Trial comparisons |
| Eptinezumab vs Placebo: Number of Participants With ≥30% Reduction From Baseline in Number of Weekly Attacks Over Weeks 1-2 | 59 of 113 | 53 of 118 | 231 | NCT04688775 | Trial comparisons |
| Eptinezumab vs Placebo: Number of Participants With ≥30% Reduction From Baseline in Number of Weekly Attacks in Week 1 | 48 of 109 | 50 of 116 | 225 | NCT04688775 | Trial comparisons |
| Eptinezumab vs Placebo: Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks in Week 1 | 36 of 109 | 28 of 116 | 225 | NCT04688775 | Trial comparisons |
| 1.5 mg SOM230 s.c. vs Placebo s.c.: deaths from any cause | 0 of 26 | 0 of 28 | 54 | NCT02619617 | Trial comparisons |
| 1.5 mg SOM230 s.c. vs Placebo s.c.: serious adverse events | 0 of 26 | 0 of 28 | 54 | NCT02619617 | Trial comparisons |
| SOM230 1.5 mg vs Placebo s.c.: Number of Participants Who Were Pain Free at 30 Minutes Post Dose | 7 of 20 | 5 of 20 | 40 | NCT02619617 | Trial comparisons |
| SOM230 1.5 mg vs Placebo s.c.: Number of Participants With Headache Response (PD Analysis Set) | 10 of 20 | 9 of 20 | 40 | NCT02619617 | Trial comparisons |
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012199
GET https://conductscience.org/api/diseases/v1/HP_0012199/drugs